Essex Woodlands Healthcare Partners
VC Fund
Palo Alto, United States
Essex Woodlands Healthcare Partners is a VC fund in Palo Alto focused on Health Care and Biotechnology. Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world's largest and most established healthcare venture capital firms. The team is comprised of 23 professionals withprincipal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience.For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing—primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.
- Total investments:
- 75
- Last investment:
- Lead investor:
- 51%
Last updated:
For AI agents: llms.txt
Industries Essex Woodlands Healthcare Partners invests in
Stages Essex Woodlands Healthcare Partners invests in
Countries Essex Woodlands Healthcare Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brooks Andrews
|
|||
Guido Neels
|
|||
Immanuel Thangaraj
|
|||
Martin Sutter
|
|||
Robert White
|
Investment Focus
Industry
- Health Care 32 (43%)
- Biotechnology 32 (43%)
- Medical 19 (25%)
- Medical Device 14 (19%)
- Pharmaceutical 11 (15%)
Stage
- Series C 15 (20%)
- Funding Round 14 (19%)
- Series D 8 (11%)
- Series B 6 (8%)
- Post-IPO Equity 6 (8%)
Country
- United States 39 (52%)
- United Kingdom 2 (3%)
- China 1 (1%)
- Canada 1 (1%)
- France 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Brooks Andrews
Associate
|
Associate | Total investments: 4 | Find email | |
|
Guido Neels
Managing Director
|
Managing Director | Total investments: 8 | Find email | |
|
Immanuel Thangaraj
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
|
Martin Sutter
Managing Director, Co-Founder
|
Managing Director, Co-Founder | Total investments: 6 | Find email | |
|
Robert White
Operating Partner
|
Operating Partner | Total investments: 4 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Boiron
|
Boiron is a Homeopathy company and has developed an app for iOS users Om_om_mo. | $925.6M / Post-IPO Equity / Oct 09, 2023 | |
Enercon Technologies
|
Enercon Technologies is an electronics manufacturing company that provides product development, testing, marketing, and design services. | May 18, 2023 | |
TELA Bio
|
TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. | $45.1M / Post-IPO Equity / Apr 18, 2023 | |
Venus Concept
|
Venus Concept is a progressive thinking company driven by their passion to create cutting edge technologies and products. While resting on strong ethical morals, they push boundaries in order to create new standards in the medical aesthetics industry.Led by a team of experienced executives and researchers, world renowned for their achievementsin the medical aesthetics industry, Venus Concept is delivering the promise of a more effective, more pleasant and more profitable experience. | $6.7M / Post-IPO Equity / Nov 18, 2022 | |
VitalConnect
|
VitalConnect develops wearable biosensor technology designed for wireless patient monitoring. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms. The company's products are designed for inpatient and outpatientsettings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. | $39M / Series E / Jan 10, 2022 | |
Metabolon
|
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. | Debt Financing / Sep 23, 2020 | |
MiMedx Group
|
MiMedx Group is a biopharmaceutical company, develops, and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. MiMedx Group’s proprietary processingmethodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications, OrthoFlo, an amniotic fluid-derived allograft for homologous applications, Physio, a bone grafting material comprising 100% bone tissue with no added carrier, and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. It also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue, AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process, and AmnioFill, a cellular tissue matrix allograft that enhances healing. MiMedX Group's products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. It sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group began operation on February 28, 2008. It has its headquarters in Marietta in Georgia. | $100M / Post-IPO Equity / Jul 02, 2020 | |
|
MiMedx Group
|
MiMedx Group is a biopharmaceutical company, develops, and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. MiMedx Group’s proprietary processingmethodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications, OrthoFlo, an amniotic fluid-derived allograft for homologous applications, Physio, a bone grafting material comprising 100% bone tissue with no added carrier, and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. It also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue, AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process, and AmnioFill, a cellular tissue matrix allograft that enhances healing. MiMedX Group's products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. It sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group began operation on February 28, 2008. It has its headquarters in Marietta in Georgia. | $100M / Post-IPO Equity / Jul 02, 2020 | |
Sonendo
|
Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $85M / Jan 06, 2020 | |
BioTissue
|
TissueTech is an innovative technology company that uses products derived from human amniotic and umbilical cord tissues. Its medical technology platform markets innovative amniotic and umbilical cord-based products, thereby enabling physicians to avail of enhanced regenerative healing technology in eye care, wound care, and orthopedics.Tissuetech was founded in 2001 and is headquartered in Miami, Florida. | $82.3M / Series C / Jun 26, 2019 | |
| See all 75 investments → | |||
Co-Investors
EW Healthcare Partners
7 deals together
MPM Capital
7 deals together
Domain Associates
6 deals together
Morgenthaler Ventures
6 deals together
SV Health Investors
6 deals together
Versant Ventures
6 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Essex Woodlands Healthcare Partners invest in?
Essex Woodlands Healthcare Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Funding Round stage. Most of the 75 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Essex Woodlands Healthcare Partners?
Public channels for Essex Woodlands Healthcare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Essex Woodlands Healthcare Partners?
The team at Essex Woodlands Healthcare Partners includes Brooks Andrews (Associate), Guido Neels (Managing Director) and Immanuel Thangaraj (Managing Director), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
